Survodutide 10mg × 10 vials

A synthetic dual glucagon/GLP-1 receptor agonist studied for metabolic research, obesity-related models, appetite-regulation pathways, glucose metabolism, liver-fat reduction research, energy expenditure mechanisms, and broader metabolic-disease research protocols.

Product Overview

Compound: Survodutide / BI 456906
Strength: 10 mg per vial
Injection type: Research protocol dependent
Frequency: Research protocol dependent

Reconstitution

Amount in vial: 10 mg
BAC water: 2 mL
Amount per unit: 50 mcg per unit

Research Dose

Protocol dependent.

Notes

Survodutide, also known as BI 456906, is described as an investigational dual agonist of the glucagon receptor and GLP-1 receptor. These receptor pathways are studied in relation to appetite regulation, energy expenditure, glucose metabolism, liver-fat metabolism, and body-weight regulation.

Research literature has examined Survodutide in obesity-related models, metabolic dysfunction-associated steatohepatitis research, liver-fat reduction, visceral-fat reduction, insulin-sensitivity pathways, and broader metabolic-disease mechanisms.

Unlike GLP-1-only receptor agonists, Survodutide is studied for combined GLP-1 and glucagon receptor activity, where GLP-1 pathways are linked with satiety and glucose regulation, while glucagon receptor activity is studied in relation to energy expenditure and hepatic fat metabolism.

Survodutide remains an investigational compound in many jurisdictions. No standard consumer dosing protocol should be assumed.

Use only within appropriate research or professional guidance frameworks.